CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

COAGHemab Therapeutics Holdings, Inc.

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $30.84 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$1.44B
CountryUSA
RECENT INSIDER TRADES
  • 2026-06-17 · RA CAPITAL MANAGEMENT, L.P. (10% Owner) · BUY
  • 2026-05-21 · RA CAPITAL MANAGEMENT, L.P. (10% Owner) · BUY
  • 2026-05-14 · RA CAPITAL MANAGEMENT, L.P. (10% Owner) · BUY
INSTITUTIONAL OWNERSHIP
Institutional holders55
Shares held36,183,003
Value$1.30B
Percent of shares outstanding77.46%
As of quarter end2026-06-30
RECENT NEWS
  • Hemab Therapeutics: The Market Is Pricing One Rung Of A Four-Rung Ladder
  • Hemab Therapeutics appoints Keli Walbert to board
  • Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
Hemab Therapeutics Holdings, Inc. (COAG) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit